سعر ريفافلوفا 20 مجم 2026

Rivaflowva (rivaroxaban) 20 mg film-coated tablets, pack of 20 (2 strips), Gypto Pharma, Egypt.

• Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation.DailyMed (NLM)
• Treatment of DVT and PE (20 mg once daily after initial 21 days of 15 mg twice daily).DailyMed (NLM)

• Active pathological bleeding.International label, same formulation · DailyMed (NLM)
• Severe hypersensitivity reaction to rivaroxaban (e.g., anaphylaxis).International label, same formulation · DailyMed (NLM)

• Boxed warning: premature discontinuation increases the risk of thrombotic events; epidural or spinal hematomas may occur with neuraxial anesthesia or spinal puncture.International label, same formulation · DailyMed (NLM)
• Increases bleeding risk, including serious or fatal bleeding; concomitant aspirin, P2Y12 inhibitors, other antithrombotics, NSAIDs, SSRIs/SNRIs increase risk; not recommended with prosthetic heart valves or triple-positive antiphospholipid syndrome.International label, same formulation · DailyMed (NLM)

• Combined P-gp and strong CYP3A inhibitors/inducersAvoid combined P-gp and strong CYP3A inhibitors (increased exposure) or inducers (decreased exposure).DailyMed (NLM)
• Anticoagulants, antiplatelets, NSAIDs/aspirinIncreased bleeding risk.DailyMed (NLM)

• Limited data are insufficient to inform drug-associated risk; use with caution because of potential pregnancy-related hemorrhage and/or emergent delivery.International label, same formulation · DailyMed (NLM)
• Rivaroxaban has been detected in human milk; effects on the breastfed child are insufficiently known.International label, same formulation · DailyMed (NLM)

• Rivaroxaban: Highly selective direct factor Xa inhibitor with oral bioavailability; inhibition of factor Xa interrupts the intrinsic and extrinsic coagulation pathways, inhibiting thrombin formation and thrombus development; does not inhibit thrombin and has no demonstrated effect on platelets (EU SmPC).